Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ · Manufacturing · Pharmaceutical preparations
$7.30+$0.2200 (+3.11%) on the dayAs of the close; data may be delayed.
PHAT price, last 12 months
Key stats
- Previous close
- $7.08
- Open
- $7.11
- Day range
- $7.10 – $7.38
- 52-week range
- $6.91 – $18.31
- Volume
- 1.3M
- Avg volume (20 days)
- 1.3M
- Market cap
- $590.6M
Performance
1W−2.4%
1M−16.8%
3M−31.9%
6M−32.3%
YTD−56.0%
1Y−37.7%
vs S&P 500, 1Y−54.4 pts
Technicals and fundamentals
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $590.6M